```
FILE 'HOME' ENTERED AT 02:21:35 ON 20 JUN 2008

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 02:22:24 ON 20 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 JUN 2008  HIGHEST RN 1029146-45-9
DICTIONARY FILE UPDATES:  18 JUN 2008  HIGHEST RN 1029146-45-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> E
"(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROPROPOXY)BENZYL)AMI
NO)-2,2,2-TRIFLUOROETHANOL"/CN 25
E1            1     (R)-1-((4,4'-DIMETHOXYTRITYL)OXY)-2-PROPANOL/CN
E2            1
(R)-1-((4-((5-METHYL-2-(4-TRIFLUOROMETHYLPHENYL)OXAZOL-4-YL)METHOXY)BENZENE)SULFONYL
)-2,3-DIHYDRO-1H-INDOLE-2-CARBOXYLIC ACID/CN
E3            0 -->
(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROPROPOXY)BENZYL)AMIN
O)-2,2,2-TRIFLUOROETHANOL/CN
E4            1
(R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID
(2,2-DIMETHYLPROPYL)AMIDE/CN
E5            1
(R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID
ISOPROPYLAMIDE/CN
E6            1
(R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID
TERT-BUTYLAMIDE/CN
E7            1     (R)-1-((4-AZIDO-3,4-DIHYDRO-2H-CHROMEN-7-YL)METHYL)PIPERIDINE/CN
E8            1     (R)-1-((4-AZIDOCHROMAN-7-YL)METHYL)-4-FLUOROPIPERIDINE/CN
E9            1     (R)-1-((4-CHLOROPHENYL)SULFONYL)-2-PROPANOL/CN
E10           1
(R)-1-((4-METHYL-3-((((4-NITROBENZYL)OXY)CARBONYL)METHYL)PHENYL)SULFONYL)-4-(5-TRIFL
UOROMETHYLPYRIDIN-2-YL)PIPERAZINE-2-CARBOXYLIC ACID METHYL ESTER/CN
E11           1     (R)-1-((4-TOLYL)SULFONYL)-2-PROPANOL/CN
E12           1     (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC
ACID (2,2-DIMETHYLPROPYL)AMIDE/CN
E13           1     (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC
ACID ISOPROPYLAMIDE/CN
```

```
E14           1     (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC
ACID TERT-BUTYL ESTER/CN
E15           1     (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC
ACID TERT-BUTYLAMIDE/CN
E16           1
(R)-1-((5,6-DIMETHOXYBIPHENYL-3-YL)CARBONYL)AZETIDINE-2-CARBOXYLIC ACID
HYDROXYAMIDE/CN
E17           1
(R)-1-((5,6-DIMETHOXYBIPHENYL-3-YL)CARBONYL)AZETIDINE-2-CARBOXYLIC ACID METHYL
ESTER/CN
E18           1
(R)-1-((5-(5-CHLOROTHIEN-2-YL)ISOXAZOL-3-YL)METHYL)-1H-INDOLE-2-CARBOXYLIC ACID
N-(1-ETHYLPYRROLIDIN-3-YL)AMIDE/CN
E19           1
(R)-1-((5-(5-CHLOROTHIEN-2-YL)ISOXAZOL-3-YL)METHYL)-1H-INDOLE-2-CARBOXYLIC ACID
N-(1-ISOPROPYLPYRROLIDIN-3-YL)AMIDE/CN
E20           1
(R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)-4-FLUOROPIPERIDINE/CN
E21           1
(R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)-4-METHYLPIPERAZINE/CN
E22           1
(R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)PIPERIDINE/CN
E23           1
(R)-1-((5-PHENYLTHIENO(3,2-B)PYRIDIN-7-YL)CARBONYL)-2-HYDROXYMETHYLPYRROLIDINE/CN
E24           1
(R)-1-((6-((3-FLUOROPHENYL)SULFONYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHYL)-1-MET
HYLUREA/CN
E25           1
(R)-1-((6-BROMO-2-PHENYL-4-QUINOLINYL)CARBONYL)-2-HYDROXYMETHYLPYRROLIDINE/CN

=> E
"(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROETHOXY)BENZYL)AMIN
O)-2,2,2-TRIFLUOROETHANOL"/CN 25
E1            1     (R)-1-((4,4'-DIMETHOXYTRITYL)OXY)-2-PROPANOL/CN
E2            1
(R)-1-((4-((5-METHYL-2-(4-TRIFLUOROMETHYLPHENYL)OXAZOL-4-YL)METHOXY)BENZENE)SULFONYL
)-2,3-DIHYDRO-1H-INDOLE-2-CARBOXYLIC ACID/CN
E3            0 -->
(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROETHOXY)BENZYL)AMINO
)-2,2,2-TRIFLUOROETHANOL/CN
E4            1
(R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID
(2,2-DIMETHYLPROPYL)AMIDE/CN
E5            1
(R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID
ISOPROPYLAMIDE/CN
E6            1
(R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID
TERT-BUTYLAMIDE/CN
E7            1     (R)-1-((4-AZIDO-3,4-DIHYDRO-2H-CHROMEN-7-YL)METHYL)PIPERIDINE/CN
E8            1     (R)-1-((4-AZIDOCHROMAN-7-YL)METHYL)-4-FLUOROPIPERIDINE/CN
E9            1     (R)-1-((4-CHLOROPHENYL)SULFONYL)-2-PROPANOL/CN
E10           1
(R)-1-((4-METHYL-3-((((4-NITROBENZYL)OXY)CARBONYL)METHYL)PHENYL)SULFONYL)-4-(5-TRIFL
UOROMETHYLPYRIDIN-2-YL)PIPERAZINE-2-CARBOXYLIC ACID METHYL ESTER/CN
E11           1     (R)-1-((4-TOLYL)SULFONYL)-2-PROPANOL/CN
E12           1     (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC
ACID (2,2-DIMETHYLPROPYL)AMIDE/CN
E13           1     (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC
ACID ISOPROPYLAMIDE/CN
E14           1     (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC
ACID TERT-BUTYL ESTER/CN
```

E15 1 (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID TERT-BUTYLAMIDE/CN
E16 1 (R)-1-((5,6-DIMETHOXYBIPHENYL-3-YL)CARBONYL)AZETIDINE-2-CARBOXYLIC ACID HYDROXYAMIDE/CN
E17 1 (R)-1-((5,6-DIMETHOXYBIPHENYL-3-YL)CARBONYL)AZETIDINE-2-CARBOXYLIC ACID METHYL ESTER/CN
E18 1 (R)-1-((5-(5-CHLOROTHIEN-2-YL)ISOXAZOL-3-YL)METHYL)-1H-INDOLE-2-CARBOXYLIC ACID N-(1-ETHYLPYRROLIDIN-3-YL)AMIDE/CN
E19 1 (R)-1-((5-(5-CHLOROTHIEN-2-YL)ISOXAZOL-3-YL)METHYL)-1H-INDOLE-2-CARBOXYLIC ACID N-(1-ISOPROPYLPYRROLIDIN-3-YL)AMIDE/CN
E20 1 (R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)-4-FLUOROPIPERIDINE/CN
E21 1 (R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)-4-METHYLPIPERAZINE/CN
E22 1 (R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)PIPERIDINE/CN
E23 1 (R)-1-((5-PHENYLTHIENO(3,2-B)PYRIDIN-7-YL)CARBONYL)-2-HYDROXYMETHYLPYRROLIDINE/CN
E24 1 (R)-1-((6-((3-FLUOROPHENYL)SULFONYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHYL)-1-METHYLUREA/CN
E25 1 (R)-1-((6-BROMO-2-PHENYL-4-QUINOLINYL)CARBONYL)-2-HYDROXYMETHYLPYRROLIDINE/CN

=> E "(R)-3-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROETHOXY)BENZYL)AMINO)-1,1,1-TRIFLUOROPROPAN-2-OL"/CN 25
E1 1 (R)-3-((4-(4,4,4-TRIFLUORO-1-(4-(5-TRIFLUOROMETHYLPYRIDIN-2-YL)PHENYL)BUTOXY)BENZOYL)AMINO)PROPIONIC ACID METHYL ESTER/CN
E2 1 (R)-3-((4-(4-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-(4-CYCLOHEXYLPHENYL)-4-OXOBUTYRYL)BENZOYL)AMINO)PROPIONIC ACID/CN
E3 0 --> (R)-3-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROETHOXY)BENZYL)AMINO)-1,1,1-TRIFLUOROPROPAN-2-OL/CN
E4 1 (R)-3-((4-(MORPHOLINO)-1,2,5-THIADIAZOL-3-YL)OXY)-1,2-PROPANEDIOL/CN
E5 1 (R)-3-((4-(TRIFLUOROMETHYL)PHENYL)AMINO)PENTANAMIDE/CN
E6 1 (R)-3-((4-(TRIFLUOROMETHYL)PHENYL)AMINO)PENTANOIC ACID/CN
E7 1 (R)-3-((4-(TRIFLUOROMETHYL)PHENYL)AMINO)PENTANOIC ACID ETHYL ESTER/CN
E8 1 (R)-3-((4-(TRIFLUOROMETHYL)PHENYL)AMINO)PENTANOIC ACID METHYL ESTER/CN
E9 1 (R)-3-((4-BENZYLPIPERAZIN-1-YL)METHYL)PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER/CN
E10 1 (R)-3-((4-BROMOPHENYL)(((4-TOLYL)SULFONYL)AMINO)METHYL)-1H-INDOLE/CN
E11 1 (R)-3-((4-BROMOPHENYL)(2-TRIFLUOROMETHYLPHENYL)METHOXY)-N-TERT-BUTYLAZETIDINE-1-CARBOXAMIDE/CN
E12 1 (R)-3-((4-BROMOPHENYL)(2-TRIFLUOROMETHYLPHENYL)METHOXY)AZETIDINE/CN
E13 1 (R)-3-((4-CHLOROPHENYL)(2-TRIFLUOROMETHYLPHENYL)METHOXY)AZETIDINE/CN
E14 1 (R)-3-((4-CHLOROPHENYL)CARBAMOYL)-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER/CN

E15 1 (R)-3-((4-CYANOBENZYL)OXY)-1H-PYRROLIDINE/CN
E16 1
(R)-3-((4-ETHOXYBENZOYL)AMINO)-2-(((1-PHENYL-3-TRIFLUOROMETHYL-1H-PYRAZOL-4-YL)CARBO
NYL)AMINO)PROPANOIC ACID/CN
E17 1
(R)-3-((4-ETHOXYBENZOYL)AMINO)-2-(((1-PHENYL-3-TRIFLUOROMETHYL-1H-PYRAZOL-4-YL)CARBO
NYL)AMINO)PROPANOIC ACID METHYL ESTER/CN
E18 1
(R)-3-((4-FLUORO-3-TRIFLUOROMETHYLBENZOYL)AMINO)PYRROLIDINE-1-CARBOXYLIC ACID
N-(7-METHOXYTHIAZOLO(5,4-D)PYRIMIDIN-2-YL)AMIDE/CN
E19 1
(R)-3-((4-FLUORO-3-TRIFLUOROMETHYLBENZYL)AMINO)PYRROLIDINE-1-CARBOXYLIC ACID
N-(7-METHOXYTHIAZOLO(5,4-D)PYRIMIDIN-2-YL)AMIDE/CN
E20 1 (R)-3-((4-METHOXYBENZYL)OXY)-2-BUTANONE/CN
E21 1 (R)-3-((4-METHOXYBENZYL)OXY)OCT-1-ENE/CN
E22 1
(R)-3-((4-METHYLSULFONYL-2-(PIPERIDIN-3-YLMETHOXY)BENZOYL)AMINO)-N-(5-CHLOROPYRIDIN-
2-YL)PYRIDINE-2-CARBOXAMIDE/CN
E23 1 (R)-3-((4-TOLYL)(((4-TOLYL)SULFONYL)AMINO)METHYL)-1H-INDOLE/CN
E24 1
(R)-3-((5-((AZETIDIN-1-YL)CARBONYL)PYRAZIN-2-YL)OXY)-5-((1-METHYL-2-OXOPYRROLIDIN-3-
YL)OXY)-N-(4-METHYL-1,3-THIAZOL-2-YL)BENZAMIDE/CN
E25 1
(R)-3-((5-((AZETIDIN-1-YL)CARBONYL)PYRAZIN-2-YL)OXY)-5-((1-METHYL-2-OXOPYRROLIDIN-3-
YL)OXY)BENZOIC ACID/CN

=>
Uploading C:\Program Files\STNEXP\Queries\10_678145 CETPI Structure.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1 SSS SAM
SAMPLE SEARCH INITIATED 02:33:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 34 TO ITERATE

100.0% PROCESSED 34 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 331 TO 1029
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> d scan L2

L2 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Propanol, 3-[[3-[3-(1,1-dimethylethyl)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-, (2R)-
MF C28 H28 F7 N O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Propanol, 3-[[3-(3-ethyl-5-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-, (2R)-
MF C27 H26 F7 N O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Propanol, 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-
MF C26 H23 Cl F7 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>
Uploading C:\Program Files\STNEXP\Queries\10_678145 CETPI Structure2.str

L3 STRUCTURE UPLOADED

=> d L3
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s L3 SSS SAM
SAMPLE SEARCH INITIATED 02:36:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       34 TO ITERATE

100.0% PROCESSED       34 ITERATIONS                                2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          331 TO     1029
PROJECTED ANSWERS:               2 TO      124

L4            2 SEA SSS SAM L3

=> d L4 1-2

L4   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   263342-63-8  REGISTRY
ED   Entered STN:  28 Apr 2000
CN   2-Propanol, 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-
     tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-  (CA INDEX NAME)
MF   C26 H23 Cl F7 N O3
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, USPAT2, USPATFULL
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
RN 263264-49-9 REGISTRY
ED Entered STN: 27 Apr 2000
CN 2-Propanol, 3-[[3-(3-ethyl-5-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-, (2R)- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H26 F7 N O3
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s L3 SSS Full
FULL SEARCH INITIATED 02:36:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 698 TO ITERATE

100.0% PROCESSED 698 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

L5 6 SEA SSS FUL L3

=> d scan L5

L5 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Propanol, 3-[[3-(3-ethyl-5-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-, (2R)-
MF C27 H26 F7 N O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L5 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Propanol, 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-
MF C26 H23 Cl F7 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Propanol, 3-[[3-(3-ethyl-5-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-
MF C27 H26 F7 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d his

(FILE 'HOME' ENTERED AT 02:21:35 ON 20 JUN 2008)

FILE 'REGISTRY' ENTERED AT 02:22:24 ON 20 JUN 2008
E "(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF
E "(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF
E "(R)-3-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF
L1 STRUCTURE UPLOADED
L2 3 S L1 SSS SAM
L3 STRUCTURE UPLOADED
L4 2 S L3 SSS SAM
L5 6 S L3 SSS FULL

=> file caplus, medline,

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	192.94	193.15

FILE 'CAPLUS' ENTERED AT 02:36:53 ON 20 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'MEDLINE' ENTERED AT 02:36:53 ON 20 JUN 2008

=> s L5
L6 20 L5

=> s L6 (P) atorvastatin
L7 0 L6 (P) ATORVASTATIN

=> and atorvastatin
AND IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s L6 and atorvastatin
L8 4 L6 AND ATORVASTATIN

=> dup rem L8
PROCESSING COMPLETED FOR L8
L9 4 DUP REM L8 (0 DUPLICATES REMOVED)

=> s L9 not pd>20021220

L10 0 L9 NOT PD>20021220

=> d L9 1-4 TI AB IBIB

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods of treatment with CETP inhibitors
AB This invention relates to cholesterol ester transfer protein (CETP) inhibitors, pharmaceutical compns. contg. such inhibitors, and the use of such inhibitors to treat certain disease/conditions optionally in combination with certain therapeutic agents, e.g., HMG CoA reductase inhibitors. Tablets contained active ingredient 0.25-100, microcryst. cellulose 200-650, fumed silica 10-650, and stearic acid 5-15 mg/tablet.
ACCESSION NUMBER: 2007:1088451 CAPLUS
DOCUMENT NUMBER: 147:392438
TITLE: Methods of treatment with CETP inhibitors
INVENTOR(S): Ruggeri, Roger Benjamin
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 58pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007107843	A1	20070927	WO 2007-IB673	20070312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
JP 2007254466	A	20071004	JP 2007-71833	20070320
PRIORITY APPLN. INFO.:			US 2006-785188P P	20060322
			US 2006-806841P P	20060710

OTHER SOURCE(S): MARPAT 147:392438
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
TI Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AB A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase inhibitor), and a concn.-enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concn. enhancement of the CETP inhibitor when administered to an aq. use environment. The solid amorphous dispersion of torcetrapib and atorvastatin provided a MDC9o for atorvastatin 5.7-fold that provided by cryst. drug.
ACCESSION NUMBER: 2006:1279173 CAPLUS
DOCUMENT NUMBER: 146:50277
TITLE: Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase

inhibitors

INVENTOR(S): Freisen, Dwayne Thomas; Hancock, Bruno Caspar; Ketner, Rodney James; Lyon, David Keith; Nightingale, James Alan Schriver; Shanker, Ravi Mysore

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 43pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006129167	A1	20061207	WO 2006-IB1407	20060522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1893178	A1	20080305	EP 2006-744791	20060522
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2005-686109P P 20050531
WO 2006-IB1407 W 20060522

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

TI Controlled release dosage forms containing cholesteryl ester transfer protein inhibitors and immediate release of HMG-CoA reductase inhibitors

AB A dosage form comprises a cholesteryl ester transfer protein inhibitor in a soly.-improved form and an HMG-CoA reductase inhibitor, wherein the dosage form provides immediate release of the HMG-CoA reductase inhibitor and controlled release of the cholesteryl ester transfer protein inhibitor. A soly.-improved from of torcetrapib was prepd. by forming a solid amorphous dispersion of torcetrapib in hydroxypropyl Me cellulose acetate succinate (HPMCAS). The dispersion was prepd. by spray-drying a soln. contg. 4.0% torcetrapib, 12.0% HPMCAS-MG (AQUOT-MG), and 84% acetone. The soln. was spray-dried by using a pressure spray nozzle.

ACCESSION NUMBER: 2005:120698 CAPLUS

DOCUMENT NUMBER: 142:225773

TITLE: Controlled release dosage forms containing cholesteryl ester transfer protein inhibitors and immediate release of HMG-CoA reductase inhibitors

INVENTOR(S): Curatolo, William John; Friesen, Dwayne Thomas; Sutton, Steven C.

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011634	A1	20050210	WO 2004-IB2457	20040721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004261058	A1	20050210	AU 2004-261058	20040721
CA 2534371	A1	20050210	CA 2004-2534371	20040721
EP 1653926	A1	20060510	EP 2004-744109	20040721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004013363	A	20061010	BR 2004-13363	20040721
CN 1863511	A	20061115	CN 2004-80029003	20040721
JP 2007501217	T	20070125	JP 2006-522426	20040721
US 20050038007	A1	20050217	US 2004-903433	20040730
IN 2006DN00059	A	20070824	IN 2006-DN59	20060103
MX 2006PA01506	A	20060515	MX 2006-PA1506	20060207
NO 2006001072	A	20060504	NO 2006-1072	20060306
PRIORITY APPLN. INFO.:			US 2003-492407P P	20030804
			WO 2004-IB2457 W	20040721

OTHER SOURCE(S): MARPAT 142:225773
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
TI Compositions of cholesteryl ester transfer protein inhibitors and HMG-COA reductase inhibitors
AB A compn. comprises (1) a solid amorphous adsorbate comprising a cholesteryl ester transfer protein (CETP) inhibitor and a substrate; and (2) an HMG-CoA reductase inhibitor is disclosed. The solid amorphous adsorbate provides concn. enhancement of the CETP inhibitor relative to a control compn. consisting essentially of the unadsorbed CETP inhibitor alone, resulting in improved bioavailability. A solid amorphous adsorbate was prepd. from torcetrapib, fumed silica (Cab-O-Sil), and mixed with granules contg. atorvastatin hemicalcium trihydrate, calcium carbonate, microcryst. cellulose, croscarmellose sodium, polysorbate, hydroxypropyl cellulose, and pregelatinized starch, and then pressed into 150 mg compacts. The resulting compacts each contained 32 mg torcetrapib and 3.2 mg atorvastatin trihydrate hemicalcium salt.
ACCESSION NUMBER: 2004:550886 CAPLUS
DOCUMENT NUMBER: 141:94364
TITLE: Compositions of cholesteryl ester transfer protein inhibitors and HMG-COA reductase inhibitors
INVENTOR(S): Babcock, Walter Christian; Friesen, Dwayne Thomas; Smithey, Daniel Tod; Shanker, Ravi Mysore
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```
     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ---------------       ----   --------    --------------------     --------
     WO 2004056395          A1    20040708    WO 2003-IB6170           20031218
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 20040132771         A1    20040708    US 2003-678145           20031006
     CA 2510458             A1    20040708    CA 2003-2510458          20031218
     WO 2004056396          A1    20040708    WO 2003-IB6240           20031218
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003285677          A1    20040714    AU 2003-285677           20031218
     AU 2003285703          A1    20040714    AU 2003-285703           20031218
     EP 1578448             A1    20050928    EP 2003-778668           20031218
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003017520          A     20051116    BR 2003-17520            20031218
     JP 2006512361          T     20060413    JP 2004-561920           20031218
     MX 2005PA06167         A     20050826    MX 2005-PA6167           20050609
PRIORITY APPLN. INFO.:                         US 2002-435328P      P  20021220
                                               WO 2003-IB6170       W  20031218
                                               WO 2003-IB6240       W  20031218
REFERENCE COUNT:          4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 02:21:35 ON 20 JUN 2008)

     FILE 'REGISTRY' ENTERED AT 02:22:24 ON 20 JUN 2008
                E "(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF
                E "(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF
                E "(R)-3-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF
L1              STRUCTURE UPLOADED
L2            3 S L1 SSS SAM
L3              STRUCTURE UPLOADED
L4            2 S L3 SSS SAM
L5            6 S L3 SSS FULL

     FILE 'CAPLUS, MEDLINE' ENTERED AT 02:36:53 ON 20 JUN 2008
L6           20 S L5
L7            0 S L6 (P) ATORVASTATIN
L8            4 S L6 AND ATORVASTATIN
L9            4 DUP REM L8 (0 DUPLICATES REMOVED)
```

L10 0 S L9 NOT PD>20021220

=> d L1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d L3
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.